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Introduction
Due to significant research efforts in the field of influenza
therapy, in the near future we will have a series of new antivirals
to treat patients with influenza. Most likely, hospitalized
patients with influenza pneumonia as well as other severe
forms of influenza will be managed with combination antiviral
therapy. During the selection of antivirals, it will be important
for physicians to have a clear understanding of the mechanisms
of action of anti-influenza medications.
In this manuscript I will review the main steps of the life cycle
of the influenza virus, classify current and future antivirals
according to the step that they inhibit in the viral life cycle, and
summarize antivirals mechanisms of actions.

Life cycle of influenza virus
The influenza viruses reach to the human respiratory tract
via droplets from a patient with active disease. Once in the
respiratory tract, viruses infect and replicate in epithelial cells.
The steps in the life cycle of influenza in a human epithelial cell
are depicted in Figure 1 [1-3]. The influenza virus contains
three membrane proteins, hemagglutinin, neuraminidase, and
matrix 2 (M2) protein. Hemagglutinin is the most abundant of
the three viral proteins, followed by neuraminidase and M2.
There are eight copies of viral RNA gene segments, viral RNA
polymerase, and other core proteins inside of the virus (Figure
1: Influenza virus).
Step 1. Attachment of influenza virus to epithelial cell
The virus uses the surface glycoprotein hemagglutinin to attach
to molecules of sialic acids present in the surface of epithelia
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cells (Figure 1: Attachment). Since sialic acids are abundant
in membranes of human epithelial cells, the virus has multiple
receptors to attach. The binding of the hemagglutinin to sialic
acid triggers the next step of viral entry into the cell.
Step 2. Endocytosis of the influenza virus
The virus enters the epithelial cell in an endosome (Figure 1:
Endocytosis). Inside the endosome, due to the low pH, there is
a conformational change of the viral hemagglutinin.
Step 3. Fusion of viral and endosomal membranes
The viral hemagglutinin fuses with the endosomal membrane
(Figure 1: Fusion). At this point, the viral membrane is in
contact with the endosomal membrane.
Step 4. Release of viral components into the cytosol
The low pH in the endosome is responsible for changes occurring
in the M2 viral membrane protein, with opening of the M2 ion
channels. As a consequence, the viral core is acidified and the
viral components are release into the cell’s cytoplasm (Figure
1: Release). From the cytoplasm, the viral proteins travel to the
cell’s nucleus.
Step 5. Transcription and replication of viral RNA
Once in the nucleus, the viral RNA polymerase carries out the
transcription and replication of the influenza genome (Figure
1: Replication of viral RNA). Replication of the viral genome
does not require a primer.
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Figure 1 Steps of the influenza life cycle in a human epithelial cell E

Step 6. Transcription and synthesis of viral messenger
RNA (mRNA)
The virus uses the viral RNA polymerase to generate mRNA
(Figure 1: Synthesis of viral mRNA). The viral RNA
polymerase is composed of three protein subunits, the PB2,
PB1, and PA. During the process of generating viral mRNA, the
viral RNA polymerase obtains a cap from the cellular mRNA,
a process called “cap-snatching”. This generates short-capped
oligomers that will serve as primers for transcription of viral
mRNA. Once the viral mRNA is formed, it is moved from the
nucleus to the cytoplasm.
Step 7. Production of viral proteins
The viral mRNA uses the cell’s ribosomes to translate all viral
proteins (Figure 1: Production of viral proteins). Some
proteins will return to the nucleus to form a complex with the
newly formed viral RNA.
Step 8. Maturation of viral proteins
Several viral proteins are taken by the Golgi apparatus. As the
proteins move through the apparatus they mature and become
ready for assembly (Figure 1: Maturation).

Step 9. Assembly
The viral RNA and the new viral proteins accumulate in the
cytoplasm, and a new virus will be assembled (Figure 1:
Assembly). The nascent virus will bulge in the cell membrane.
Step 10. Budding
During the budding process, the virus will use some of the
cell’s membrane to form the new viral envelope (Figure 1:
Budding). The ion channel M2 protein contributes to the
budding of the virus by functioning as a membrane-bending
protein.
Step 11. Release of new viruses
Once the new influenza virus buds from the cell, the virus
remains attached to the cell’s sialic acid receptor. The viral
neuraminidase has sialidase activity. By altering sialic acid, the
neuraminidase is able to release new viruses (Figure 1: Viral
release).

ULJRI Vol 3, (1) 2019

2

Figure 2 Classification of antivirals according to the step they inhibit in the influenza life cycle.

Antiviral medications to treat influenza
Antiviral medications classified according to the steps that
they block in the viral life cycle are depicted in Figure 2. The
mechanisms of action of each antiviral medication and spectrum
of action against influenza A and B viruses will be reviewed.
Antivirals acting on Step 1: Attachment of influenza
virus to epithelial cell
Anti-Hemagglutinin Monoclonal Antibodies
Several monoclonal antibodies are being developed which target
the highly conserved stem region of the hemagglutinin molecule
of the virus [4]. By blocking the hemagglutinin, the virus is
not able to attach to the sialic acid receptors. These antibodies
bind to the more conserved stalk portion of the hemagglutinin
molecule, and thus, they have broad antiviral activity against
several influenza A subtypes. Some of the antibodies in clinical
development include MEDI8852, MHAA4549A, VIS- 410,
CT-P27, CR6261, and CR8020. There is also in development
an antibody targeting the hemagglutinin of influenza B
(MHAB5553A).
Fludase (DAS181)
Fludase adheres to the membrane of the epithelial cells and
cleaves the sialic acid from the cell surface [5]. Without sialic
acid in the cell membrane, the virus has no receptor to attach.
Fludase is delivered as an aerosolized nebulizer formulation,
which allows the drug to remove the sialic acid of the epithelial
cells in the area of infection. Since sialic acid is the human
receptor for all influenza viruses, the drug has activity against all
types of influenza viruses. This drug is not approved in the US.

Antivirals acting on Step 4: Release of viral components
into the cytosol
Amantadine and Rimantadine
These drugs block the M2 ion channel protein, inhibiting the
release of core viral proteins into the cytoplasm. They only block
M2 ion channel proteins of influenza A viruses. Therefore, these
medications are not active against influenza B viruses. Due to
the high levels of resistance to these drugs among the currently
circulating influenza A viruses, the CDC recommends that
amantadine and rimantadine not be used in clinical practice [6].
Antivirals acting on Step
replication of viral RNA

5.

Transcription

and

Favipiravir
Favipiravir is a potent inhibitor of the viral RNA polymerase
and block the replication of the influenza viral genome [7]. The
drug is ribosylated and phosphorylated intracellularly to form
favipiravir-RTP, which is the active form of the drug. This form
of the drug is recognized by the viral RNA polymerase and
incorporated into an emerging viral RNA as a purine which
results in chain termination during RNA synthesis. Favipiravir
has a broad spectrum of activity against influenza viruses.
The spectrum of activity also includes RNA viruses other
than influenza. Favipiravir has a risk for teratogenicity and
embryotoxicity. The drug is currently approved for influenza
infection in Japan but is not approved in the US.
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Antivirals acting on Step 6: Transcription and synthesis
of viral mRNA

antiviral medications will be necessary when selecting therapy
for patients hospitalized with severe influenza.

Baloxavir marboxil
Baloxavir targets the cap-dependent endonuclease in the PA
subunit of the viral RNA polymerase and acts by inhibiting
the process known as cap snatching [8]. This will block the
production of the primers necessary for transcription of the viral
mRNA. Baloxavir has activity against Influenza A and B viruses.
The prodrug baloxavir marboxil is converted by hydrolysis to
the active form, baloxavir acid. The drug, that is administered as
a single dose by mouth, was recently approved in the US.

Funding Source: No funding sources declared.
Conflict of Interest: None reported.

Pimodivir
Pimodivir targets the PB2 subunit of the viral RNA polymerase
and acts by preventing the cap-snatching activity of the influenza
viral polymerase [9]. Pimodivir inhibits the synthesis of viral
mRNA of influenza A viruses, but is inactive against influenza
B virus due to structural differences in the PB2 cap-binding
pocket. This drug is not approved in the US.
Antivirals acting on Step 8: Maturation of viral proteins
Nitazoxanide
Nitazoxanide blocks maturation of the viral glycoprotein
hemagglutinin [10]. The drug had no effect on the other
glycoprotein, neuraminidase, or the M2 protein. The drug is
orally administered and is deacetylated in the blood to the active
metabolic form tizoxanide. The drug is not approved in the US
for treatment of influenza.
Antivirals acting on Step 10: Budding of new viruses
Anti-M2 Protein Monoclonal Antibodies
There is an antibody targeting the M2 protein of the influenza
A virus (TCN032) [11]. The antibody binds to the M2 which is
exposed during the budding of the new virus on the surface of
infected cells. The drug prevents virus budding and thus acts by
a different mechanism from the M2 ion channel inhibitors. This
drug is not approved in the US.
Antivirals acting on Step 11: Release of new viruses
Oseltamivir, Zanamivir, Peramivir, and Laninamivir
These drugs target the glycoprotein neuraminidase. By
inhibiting the neuraminidase, they block the detachment of
the virus from the sialic acid moieties on the epithelial cell.
Neuraminidase inhibitors have activity against both influenza
A and B viruses. Oseltamivir, zanamivir, and peramivir are
approved in the US. Peramivir is an intravenous formulation
[12]. Laninamivir is approved in Japan but not in the US [13].

Conclusions
Our options to treat hospitalized patients with influenza infection
will continue to expand. Some of the new drugs have improved
effectiveness compared to currently available drugs when
treatment is initiated beyond 48 hours after symptom onset.
Antivirals combinations with drugs which inhibit different steps
of the influenza life cycle could become the standard approach
for managing complicated patients. Combination therapy
may also decrease the risk for the selection of viral resistance.
Comprehensive understanding of the mechanisms of actions of
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